Novel therapies for malignant gliomas

被引：41

作者：

Cavaliere, Robert

Wen, Patrick Y.

Schiff, David

机构：

[1] Ohio State Univ, Div Neurooncol, Columbus, OH 43210 USA

[2] Dana Farber Brigham & Womens Hosp, Ctr Neurooncol, Boston, MA 02115 USA

[3] Univ Virginia, Hlth Sci Ctr, Neuro Oncol Ctr, Charlottesville, VA 22908 USA

来源：

NEUROLOGIC CLINICS | 2007年 / 25卷 / 04期

关键词：

D O I：

10.1016/j.ncl.2007.07.012

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The impact of cytotoxic therapies on the outcome of glioblastoma has been modest thus far. Yet it is clear that subsets of high-grade gliomas exist that are sensitive to treatment. Patients deemed resistant to the current standard approach may be selected for alternative therapies, thereby avoiding treatment toxicity from an ineffective treatment. The future of novel therapies lies in our understanding of the molecular biology of gliomas and their stem cells. Not only will this drive the development of new agents, it will also lead to tailored therapies for specific tumors. Yet much research is still needed at all levels, from the identification of molecular markers to the development and application of novel therapeutics.

引用

页码：1141 / +

页数：32

共 162 条

[71]

Hellström M, 1999, DEVELOPMENT, V126, P3047

[72]

HERMANSON M, 1992, CANCER RES, V52, P3213

[73]

Hockaday DC, 2005, J NUCL MED, V46, P580

[74] Gefitinib accumulation in glioblastoma tissue [J].